A number of studies have shown that ACSS2 gene deletion can inhibit the growth of a variety of cancers, including the above-mentioned breast cancer, prostate cancer, liver cancer, glioblastoma, esophageal cancer, kidney cancer, lung cancer, and other common tumors. This evidence concerns the gene ACSS2 and prostate carcinoma.